Pennine Acute Trust is top recruiter of patients into lung disease study

lung study
Pennine Acute Trust is top recruiter of patients into lung disease study
14 August 2015

RESEARCH nurses from The Pennine Acute Hospitals NHS Trust have been the top recruiters nationwide over the past three months for a genetic study into interstitial lung disease. 

Fifty participants were recruited by research nurses including Denise McSorland, Dionne Dervin, Jonathon Ogor, and Paula Mulligan.  This brings the total recruitment at Pennine Acute Trust which runs North Manchester General Hospital, The Royal Oldham Hospital, Fairfield General Hospital in Bury, Rochdale Infirmary and community services to a total of over 120 participants.

The study is led by consultant chest physician Dr Zoe Borrill, and supported by Drs. Nita Sehgal, Jenny Hoyle, Georges Ng Man Kwong and Mark Longshaw.

Interstitial lung disease (ILD) is an umbrella term that covers many different conditions.  ‘Interstitial’ means the disease affects the interstitium, a lace-like network of tissue that supports the alveoli (air sacs) in your lungs.  There are more than 200 different types of ILD. Idiopathic pulmonary fibrosis (IPF) is the most common type of ILD and idiopathic means that there is no obvious cause for the disease.

When you have ILD, inflammation or scar tissue builds up in your lungs, making them thick and hard. This build-up of scar tissue is called fibrosis and as your lungs become stiffer and lose their elasticity, you are less able to take oxygen from the air that you breathe. People with ILD can feel breathless from simple everyday activities such as walking. Coughing is another common symptom.

Linda Kent, senior research nurse at Pennine Acute Trust, said: “The ILD study is carried out in collaboration with the Universities of Bath, Manchester and Liverpool.  The study complements the drug trial ‘Riff’ that is running successfully at Pennine Acute and tries to see if the drug Lebrikizumab works in patients with idiopathic pulmonary fibrosis.   Treatment options for this group of patients are limited, so studies of new drugs are very important.

“The respiratory team is committed to providing patients with the opportunity to participate in high quality research in lung diseases.”

The team is also working on studies into the assessment of asthma control, and in early autumn are starting a study to assess a very accurate genetic test in patients with severe asthma.  

There will also be an opportunity for patients with bronchiectasis to join a new UK wide registry.  Bronchiectasis is a chronic lung condition that can lead to repeated chest infections, and distressing symptoms including chronic cough and shortness of breath.

Dr Zoe Borill, said: “Participation in clinical research gives clear benefits to patients, staff and the organisation.  These studies have provided patients with new opportunities to become involved in research which will provide very useful information in the future treatment of lung diseases.”

Pictured left to right: Dionne Dervin, research nurse;  Dr Zoe Borrill, consultant chest physician; Denise McSorland, senior research nurse.